Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial

Giuseppe Derosa, Arrigo F.G. Cicero, Angela D'Angelo, Elena Fogari, Sibilla Salvadeo, Alessia Gravina, Ilaria Ferrari, Raffaella Fassi, Roberto Fogari
  • Clinical Therapeutics, April 2007, Elsevier
  • DOI: 10.1016/j.clinthera.2007.03.015

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Arrigo FG CICERO